SCHEMBL5214925

SCHEMBL5214925

Cc1nc(-c2ccccc2)c(C)o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 1/20 0.58
MAPK12 P53778 1/20 0.58
MAPK11 Q15759 1/20 0.58
MAPK14 Q16539 1/20 0.58
KDM4E B2RXH2 7/20 0.56
ALDH1A1 P00352 5/20 0.56
PTGS2 P35354 2/20 0.50
KMT2A Q03164 3/20 0.49
POLB P06746 2/20 0.49
PTGS1 P23219 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
HPGD P15428 3/20 0.44
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089931 0.81 KDM4E (0.56) KDM4EALDH1A1PTGS2POLBPTGS1
SCHEMBL2091239 0.81 MAPK13 (0.83) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL10263008 0.80 RAB9A (0.47) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL31469380 0.79 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL15578111 0.79 ACHE (0.43) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL18865626 0.79 KDM4E (0.40) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL15716348 0.79 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL5544700 0.79 PTGS2 (0.54) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL5536993 0.79 ALDH1A1 (0.47) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL5538991 0.79 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
EP-2380891-A1 Substituted piperidino-dihydrothienopyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 EP disclosed
EP-2128146-A1 HETEROCYCLIC COMPOUNDS AND HETEROCYCLIC POLYMERS Sumitomo Chemical Company, Limited (JP) 2009-12-02 EP disclosed
US-7268201-B2 Insulating-film forming material and insulating film using the same FUJIFILM CORPORATION (JP) 2007-09-11 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed
US-4596816-A Pharmaceuticals TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-06-24 US disclosed
EP-0092239-A2 Oxazole derivatives, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1983-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPK13 1172/4885MAPK12 1975/4885MAPK11 1455/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPK13 1600/4885MAPK12 1611/4885MAPK11 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.